​

Funding Round

Series C - Ajax Therapeutics

Series C - Ajax Therapeutics

Investment Firm

Overview

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Announced Date

May 13, 2024

Closed on Date

May 13, 2024

Funding Type

Series C

Highlights

Location

United States, North America

Social

N/A

Investor Lead

Goldman Sachs Asset Management

Goldman Sachs Asset Management

Goldman Sachs Asset Management is a debt and early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

8

Investor Name
Participant InvestorRA Capital Management
Participant InvestorEcoR1 Capital
Participant InvestorSchrödinger
Participant InvestorPoint72 Ventures
Participant InvestorVivo Capital

Round Details and Background

Ajax Therapeutics raised $95000000 on 2024-05-13 in Series C

Ajax Therapeutics is a biotechnology company developing therapies to target cytokine signaling pathways that drive hematologic malignancies.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 01, 2021
Venture Round - Ajax Therapeutics
6-40.0M
May 13, 2024
Series C - Ajax Therapeutics
9-95.0M
Jun 28, 2019
Venture Round - Ajax Therapeutics
-8.0M

Recent Activity

There is no recent news or activity for this profile.